南旧金山 - 凯赛制药公司 (NASDAQ:CASI) 周四宣布，中国国家药品监督管理局 (NMPA)已批准其抗CD38单克隆抗体CID-103用于慢性活动性肾移植抗体介导排斥反应 (AMR)患者的临床试验申请。这家市值仅为2100万美元的微型生物科技公司，尽管近期市场波动，其股票年初至今仍录得显著的20%涨幅。

Scott Moreland, who first joined Army CID in June 2004, has worked his way through various departments and leadership roles ...

CID officials reach Ballari to investigate four cases linked to New Year's Day violence that killed a Congress worker; local ...

A discussion was held with Chief Minister Siddaramaiah on transferring both the cases to CID and accordingly order has been ...